4502 Takeda Pharmaceutical Company Limited - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4502

TSE Prime

Takeda Pharmaceutical Company Limited

4,410

JPY

-63

(-1.41%)

Dec 5, 3:30 pm JST

28.52

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

4,420

Dec 5, 5:16 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	3,569,006	460,844	302,571	230,059	147.1	180	May 11, 2022	IFRS
Mar, 2023	4,027,478	490,505	375,090	317,017	204.3	180	May 11, 2023	IFRS
Mar, 2024	4,263,762	214,075	52,791	144,067	92.1	188	May 9, 2024	IFRS
Mar, 2025	4,581,551	342,586	175,084	107,928	68.4	196	May 8, 2025	IFRS
Mar, 2026 Guidance	4,500,000	400,000	243,000	153,000	96.9	200	Oct 30, 2025	IFRS
YoY	-1.8%	+16.8%	+38.8%	+41.8%	+41.7%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 13, 2020	3,250,000	355,000	200,000	60,000	180	IFRS
	Jul 31, 2020	3,250,000	395,000	230,000	92,000	180	IFRS
	Oct 29, 2020	3,200,000	434,000	258,000	124,000	180	IFRS
	Feb 4, 2021	3,200,000	434,000	258,000	180,500	180	IFRS
Results	May 11, 2021	3,197,812	509,269	366,235	376,005	180	IFRS
Mar, 2022	May 11, 2021	Available in future release
	Oct 28, 2021
	Feb 3, 2022
Results	May 11, 2022
Mar, 2023	May 11, 2022
	Oct 27, 2022
Results	May 11, 2023
Mar, 2024	May 11, 2023
	Oct 26, 2023
Results	May 9, 2024
Mar, 2025	May 9, 2024
	Oct 31, 2024
	Jan 30, 2025
Results	May 8, 2025
Mar, 2026	May 8, 2025	4,530,000	475,000	307,000	228,000	200	IFRS
	Oct 30, 2025	4,500,000	400,000	243,000	153,000	200	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	963,480	+4.4	Available in future release
Mar, 2002	1,005,060	+4.3
Mar, 2003	1,046,081	+4.1
Mar, 2004	1,086,431	+3.9
Mar, 2005	1,122,960	+3.4
Mar, 2006	1,212,207	+7.9
Mar, 2007	1,305,167	+7.7
Mar, 2008	1,374,802	+5.3
Mar, 2009	1,538,336	+11.9
Mar, 2010	1,465,965	-4.7
Mar, 2011	1,419,385	-3.2
Mar, 2012	1,508,932	+6.3
Mar, 2013	1,557,005	+3.2
Mar, 2014	1,691,685	+8.6
Mar, 2015	1,777,824	+5.1
Mar, 2016	1,807,378	+1.7
Mar, 2017	1,732,051	-4.2
Mar, 2018	1,770,531	+2.2
Mar, 2019	2,097,224	+18.5
Mar, 2020	3,291,188	+56.9
Mar, 2021	3,197,812	-2.8
Mar, 2022	3,569,006	+11.6
Mar, 2023	4,027,478	+12.8
Mar, 2024	4,263,762	+5.9
Mar, 2025	4,581,551	+7.5
Mar, 2026 Guidance	4,500,000	-1.8	400,000	+16.8	243,000	+38.8	96.9	+41.7

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	4,263,762	214,075	5.02	2.11	0.99	0.29	92.1
Mar, 2025	4,581,551	342,586	7.48	1.52	0.74	0.31	68.4
Mar, 2026 Guidance	4,500,000	400,000	8.89	2.15	1.06	0.31	96.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	4,581,551	509,269	585,019	376,005	419.0
Fiscal Year	Mar, 2025	Mar, 2021	Mar, 2007	Mar, 2021	Mar, 2008

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	2,052,707	235,552	155,068	150,261	96.8	90	May 11, 2023	IFRS
Oct - Mar, 2023	2,162,055	94,845	13,738	102,702	65.7	94	May 9, 2024	IFRS
Oct - Mar, 2024	2,197,523	-7,990	-80,892	-79,366	-50.3	98	May 8, 2025	IFRS
Oct - Mar, 2025 Guidance	2,280,519	146,439	64,196	40,559	25.7	100	Oct 30, 2025	IFRS
YoY	+3.8%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	490,505	370,054	977,156	-607,102	-709,148	533,530	3.82	IFRS
Mar, 2024	214,075	252,482	716,344	-463,862	-354,416	457,800	3.03	IFRS
Mar, 2025	342,586	690,122	1,057,182	-367,060	-751,425	385,113	2.70	IFRS

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	2,101,707	119,230	39,053	41,365	26.5	74.0	Oct 26, 2023	IFRS
Apr - Sep, 2024	2,384,028	350,576	255,976	187,294	118.9	146.2	Oct 31, 2024	IFRS
Apr - Sep, 2025	2,219,481	253,561	178,804	112,441	71.6	73.6	Oct 30, 2025	IFRS
YoY	-6.9%	-27.7%	-30.1%	-40.0%	-39.8%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	1,111,186	104,914	61,260	105,720	67.6	9.4	Feb 1, 2024	IFRS
Jan - Mar, 2024	1,050,869	-10,069	-47,522	-3,018	-1.9	-1.0	May 9, 2024	IFRS
Apr - Jun, 2024	1,207,990	166,329	136,604	95,248	60.7	13.8	Jul 31, 2024	IFRS
Jul - Sep, 2024	1,176,038	184,247	119,372	92,046	58.4	15.7	Oct 31, 2024	IFRS
Oct - Dec, 2024	1,144,124	66,942	26,407	23,789	15.1	5.9	Jan 30, 2025	IFRS
Jan - Mar, 2025	1,053,399	-74,932	-107,299	-103,155	-65.3	-7.1	May 8, 2025	IFRS
Apr - Jun, 2025	1,106,685	184,566	150,630	124,243	79.4	16.7	Jul 30, 2025	IFRS
Jul - Sep, 2025	1,112,796	68,995	28,174	-11,802	-7.5	6.2	Oct 30, 2025	IFRS
YoY	-5.4%	-62.6%	-76.4%	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	836,753	-2.6	Available in future release
Jan - Mar, 2021	770,274	-0.2
Apr - Jun, 2021	949,603	+18.4
Jul - Sep, 2021	844,820	+7.1
Oct - Dec, 2021	901,294	+7.7
Jan - Mar, 2022	873,289	+13.4
Apr - Jun, 2022	972,465	+2.4
Jul - Sep, 2022	1,002,306	+18.6
Oct - Dec, 2022	1,096,551	+21.7
Jan - Mar, 2023	956,156	+9.5
Apr - Jun, 2023	1,058,618	+8.9
Jul - Sep, 2023	1,043,089	+4.1
Oct - Dec, 2023	1,111,186	+1.3
Jan - Mar, 2024	1,050,869	+9.9
Apr - Jun, 2024	1,207,990	+14.1
Jul - Sep, 2024	1,176,038	+12.7
Oct - Dec, 2024	1,144,124	+3.0
Jan - Mar, 2025	1,053,399	+0.2
Apr - Jun, 2025	1,106,685	-8.4
Jul - Sep, 2025	1,112,796	-5.4	68,995	-62.6	28,174	-76.4	-7.5	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,207,990	248,552	222,978	197,098	185.6
Fiscal Year	Jun, 2024	Jun, 2021	Jun, 2021	Mar, 2021	Jun, 2017

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	4,087.49	45.5	13,957,750	6,354,122	1,541,146	0.69	May 11, 2023	IFRS
Mar, 2024	4,635.56	48.1	15,108,792	7,273,264	1,391,203	0.67	May 9, 2024	IFRS
Mar, 2025	4,407.01	48.7	14,248,344	6,935,084	1,187,586	0.65	May 8, 2025	IFRS
Apr - Sep, 2025	4,514.26	49.3	14,470,300	7,130,697	1,148,658	0.65	Oct 30, 2025	IFRS

Takeda Pharmaceutical Company Limited(4502) Financial Results